Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.
about
Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.Tools for predicting the PK/PD of therapeutic proteins.Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation.Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor-α in Plasma Using Minimal Physiologically Based Pharmacokinetic Models.Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model.Orthogonal tools to help determine the required selectivity of ligand-binding assays in drug development.Dose selection of siltuximab for multicentric Castleman's disease.Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis.
P2860
Q31091923-C7425A3D-7101-4008-93FC-16E64741FD38Q38355263-C4156DF9-1087-49F9-9B5A-0AAAD817E31EQ38364466-C8A54205-309C-45C3-B558-EE87AF433A8EQ38455786-37400F3F-7C30-4964-839B-E958B150B770Q38728589-89536BF1-8E08-4B6B-9164-2C001E2DA197Q38987211-0B28E35B-550A-464A-BFD6-B3FC3D6D993CQ41953134-B7F0803D-1BF9-4FF0-A07B-5D3A6A797D92Q45946525-15924F17-36D1-4A93-B281-528DD139C17CQ51057357-1AE2EFC4-5695-4000-A794-D29291B6189DQ53224491-B29F69D6-C7AF-49EF-BE13-AF84DF981C19Q53281208-06D61DE6-031E-4FDC-AAE2-229BD7A613E7Q53574282-11D587DD-522D-49BE-9968-19D52940A379Q55091235-5125E893-0F85-4781-8ADA-2B226926FE27
P2860
Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Mechanistic pharmacokinetic/ta ...... target in cynomolgus monkeys.
@en
type
label
Mechanistic pharmacokinetic/ta ...... target in cynomolgus monkeys.
@en
prefLabel
Mechanistic pharmacokinetic/ta ...... target in cynomolgus monkeys.
@en
P2093
P2860
P1433
P1476
Mechanistic pharmacokinetic/ta ...... target in cynomolgus monkeys.
@en
P2093
Damien Fink
Honghui Zhou
Hugh M Davis
Rajitha Doddareddy
Thomas McIntosh
Weirong Wang
Xiaofeng Wang
P2860
P2888
P304
P356
10.1208/S12248-013-9545-8
P407
P577
2013-11-28T00:00:00Z
P6179
1007688318